Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2021

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2021		2020		2021		2020
Net product sales	$	11,243	$	10,197	$	33,446	$	30,555
Alliance revenues	194		184		495		452
Other revenues	187		159		459		443
Total Revenues	$	11,624	$	10,540	$	34,400	$	31,450

Revenue Recognition Gross-To-Net Adjustments [Table Text Block]

The following table summarizes GTN adjustments:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2021		2020		2021		2020
Gross product sales	$	17,335	$	15,211	$	49,676	$	43,685
GTN adjustments(a)
Charge-backs and cash discounts	(1,908)		(1,440)		(5,214)		(4,072)
Medicaid and Medicare rebates	(2,625)		(2,146)		(6,482)		(5,126)
Other rebates, returns, discounts and adjustments	(1,559)		(1,428)		(4,534)		(3,932)
Total GTN adjustments	(6,092)		(5,014)		(16,230)		(13,130)
Net product sales	$	11,243	$	10,197	$	33,446	$	30,555

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $10 million and $282 million for the three and nine months ended September 30, 2021, and $(25) million and $91 million for the three and nine months ended September 30, 2020, respectively.

Revenue from External Customers by Products and Services [Table Text Block]

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2021		2020		2021		2020
Prioritized Brands
Revlimid	$	3,347	$	3,027	$	9,493	$	8,826
Eliquis	2,413		2,095		8,091		6,899
Opdivo	1,905		1,780		5,535		5,199
Orencia	870		826		2,442		2,290
Pomalyst/Imnovid	851		777		2,478		2,235
Sprycel	551		544		1,562		1,576
Yervoy	515		446		1,481		1,211
Abraxane	266		342		876		950
Empliciti	82		96		253		290
Reblozyl	160		96		400		159
Inrebic	22		13		54		40
Onureg	21		3		48		3
Zeposia	40		2		86		3
Breyanzi	30		—		47		—
Abecma	71		—		95		—
Established Brands
Vidaza	36		106		135		390
Baraclude	105		100		327		343
Other Brands	339		287		997		1,036
Total Revenues	$	11,624	$	10,540	$	34,400	$	31,450
United States	$	7,296	$	6,542	$	21,694	$	19,795
Europe	2,661		2,453		7,903		7,156
Rest of the World	1,391		1,361		4,172		4,030
Other(a)	276		184		631		469
Total Revenues	$	11,624	$	10,540	$	34,400	$	31,450

(a)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.